ACUTE LEUKEMIA

SATURDAY, DECEMBER 5, 2020

27 Phase 3, Multicenter, Open-Label Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3\textsuperscript{mut+}) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy

616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel combination therapies in treatment of newly diagnosed AML
Wang et al
Saturday, December 5, 2020: 8:15 AM

162 CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T Cell Therapy
Zhang et al
Saturday, December 5, 2020: 12:45 PM

273 Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: MRD and Novel molecular Markers
Stahl et al
Saturday, December 5, 2020: 2:15 PM

269 Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

612. Acute Lymphoblastic Leukemia: Clinical Studies: Innovative Chemotherapy and Immunotherapy Strategies in Frontline and Relapsed Disease
Shah et al
Saturday, December 5, 2020: 2:45 PM

SUNDAY, DECEMBER 6, 2020

312 Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hematologic Malignancies and COVID-19
Ramón et al
Sunday, December 6, 2020: 9:30 AM

459 Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial

613. Acute Myeloid Leukemia: Potpourri of Potential Practice Changing Studies
Wang et al
Sunday, December 6, 2020: 2:15 PM

MONDAY, DECEMBER 7, 2020

589 Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation I
Pratz et al
Monday, December 7, 2020: 9:15 AM

635 Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders

615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation II
Lancet et al
Monday, December 7, 2020: 12:15 PM